Enveric Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release (Form 10-Q) | 13 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash Balance Quarterly10.3MTarget: Sufficient to fund operations and planned IND filing into Q1 2027
EB-003 Preclinical Development Progress QuarterlyTarget: Completion of IND-enabling GLP genotoxicity and phototoxicity studies
Quarterly Net Loss Quarterly-1.6MTarget: Minimize cash burn through disciplined R&D and G&A spending
Watch Items
- EB-003 IND Application SubmissionTrigger: Submission to the FDAAction: Transition lead asset EB-003 into Phase 1 first-in-human clinical trials
- Going Concern StatusTrigger: Cash runway drops below 6 monthsAction: Execute additional capital raises via ATM program or private placements
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price falls below $1.00 for 30 consecutive business daysAction: Implement the board-approved reverse stock split (range of 1-for-5 to 1-for-15)
Research as of 20 Jun 2026